Product Description
Sincalide is a synthetic C-terminal octapeptide identical to the sequences of the endogenous cholecystokinin hormone. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Sincalide)
Mechanisms of Action: Imaging Agent
Novel Mechanism: No
Modality: Diagnostic Agent
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Australia | Canada | Ireland | United States
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
08/08/2023 |
News Article |
Fresenius Kabi Further Expands Radiology Portfolio with Launch of Gadobutrol Injection |
|
06/21/2023 |
News Article |
Fresenius Kabi Broadens Radiology Portfolio with its First-to-Market Authorized Generic, Sincalide for Injection |
|
03/11/2022 |
News Article |
Olympia Pharmacy Issues Voluntary Nationwide Recall of Seven Compounded Products due to Being Out-Of-Specification |
|
03/11/2022 |
News Article |
Olympia Pharmacy Issues Voluntary Nationwide Recall of Seven Compounded Products due to Being Out-Of-Specification |